deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT01519960

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Sponsor: Hoffmann-La Roche

Conditions Hepatitis B, Chronic
Interventions peginterferon alfa-2a [Pegasys]
Updated 24 times since 2017 Last updated: Oct 26, 2022 Started: Jul 11, 2012 Primary completion: Jul 9, 2015 Completion: Oct 18, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hepatitis B, Chronic, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 24 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Dec 2021 · 8 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Dec 2022 · 10 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2022 — Dec 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 19 earlier versions

  1. Dec 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Dec 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Sep 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Mar 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  13. Dec 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  14. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  17. May 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE3

  18. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Beijing, China , Birmingham, United Kingdom , Bologna, Italy , Boston, United States , Brussels, Belgium , Bydgoszcz, Poland , Changchun, China , Chongqing, China , Ghent, Belgium and 24 more locations